

# SEQUENCE LISTING

<110> BioInvent International AB  
<120> Formulation

<130> BIOBX/P42377PC

<150> US 61/017290  
<151> 29 December 2007

<160> 4

<170> SeqWin99

<210> 1  
<211> 1353  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antibody 2D03 Heavy Chain

<400> 1  
gaggtgcagc tgttgagtc tgggggaggc ttggtacagc ctgggggggtc cctgagactc 60  
tcctgtgcag cctctggatt caccttcagt aacgcctgga tgagctgggt ccgccaggct 120  
ccagggaagg ggctggagtg ggtctcaagt attagtgttg gtggacatag gacatattat 180  
gcagattccg tgaagggccg gtccaccatc tccagagaca attccaagaa cacgctgtat 240  
ctgcaaatga acagcctgag agccgaggac actgccgtgt attactgtgc acggatacgg 300  
gtgggtccgt ccggcggggc ctttgactac tggggccagg gtacactggt caccgtgagc 360  
tcagcctcca ccaaggggccc atcgggtcttc cccctggcac cctcctccaa gagcacctct 420  
ggggggcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggtgacgggtg 480  
tcgtggaact caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc 540  
tcaggactct actccctcag cagcgtgggt accgtgccct ccagcagctt gggcacccag 600  
acctacatct gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gaaagttgag 660  
cccaaattct gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga actcctgggg 720  
ggaccgtcag tcttctctct ccccccaaaa cccaaggaca ccctcatgat ctcccggacc 780  
cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac 840  
tggtagctgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac 900  
aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc 960  
aaggagtaca agtgcaaggc ctccaacaaa gccctcccag ccccatcga gaaaaccatc 1020  
tccaaagcca aagggcagcc ccgagaacca cagggtgtaca ccctgcccc atcccgggat 1080  
gagctgacca agaaccaggc cagcctgacc tgctgtgtca aaggcttcta tcccagcgac 1140  
atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc 1200  
gtgctggact ccgacggctc cttcttctc tacagcaagc tcaccgtgga caagagcagg 1260  
tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac 1320  
acgcagaaga gcctctccct gtctccgggt aaa 1353

<210> 2  
<211> 648  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antibody 2D03 Light Chain

<400> 2  
cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60  
tcctgtctctg gaagcaacac caacattggg aagaactatg tatcttggtg tcagcagctc 120  
ccaggaacgg cccccaact cctcatctat gctaatagca atcggccctc aggggtccct 180

gaccgattct	ctggctccaa	gtctggcacc	tcagcctccc	tggccatcag	tgggctccgg	240
tccgaggatg	aggctgatta	ttactgtgcg	tcattgggatg	ccagcctgaa	tgggtgggta	300
ttcggcgag	gaaccaagct	gacggtccta	ggtcagccca	aggctgcccc	ctcggtcact	360
ctgttcccg	cctcctctga	ggagcttcaa	gccaacaagg	ccacactggt	gtgtctcata	420
agtgacttct	acccggggagc	cgtgacagt	gcctggaagg	cagatagcag	ccccgtcaag	480
gcgggagtg	agaccaccac	accctccaaa	caaagcaaca	acaagtacgc	ggccagcagc	540
tatctgagcc	tgacgcctga	gcagtgggag	tcccacagaa	gctacagctg	ccaggtcacg	600
catgaaggga	gcaccgtgga	gaagacagt	gccctacag	aatgttca		648

<210> 3

<211> 451

<212> PRT

<213> Artificial Sequence

<220>

<223> Antibody 2D03 Heavy Chain translated sequence

<400> 3

Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1				5					10					15	

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asn	Ala
			20					25					30		

Trp	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
			35				40					45			

Ser	Ser	Ile	Ser	Val	Gly	Gly	His	Arg	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
	50					55					60				

Lys	Gly	Arg	Ser	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr
65					70				75					80	

Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
			85						90					95	

Ala	Arg	Ile	Arg	Val	Gly	Pro	Ser	Gly	Gly	Ala	Phe	Asp	Tyr	Trp	Gly
			100					105					110		

Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser
		115					120					125			

Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala
	130					135					140				

Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val
145					150					155					160

Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala
			165						170					175	

Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val
			180					185					190		

Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His
		195					200					205			

Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys
	210						215				220				

Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

225	230	235	240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met	245	250	255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His	260	265	270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val	275	280	285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr	290	295	300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly	305	310	315
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile	325	330	335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val	340	345	350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser	355	360	365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu	370	375	380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro	385	390	395
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val	405	410	415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met	420	425	430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser	435	440	445
Pro Gly Lys	450		
<210>	4		
<211>	216		
<212>	PRT		
<213>	Artificial Sequence		
<220>			
<223>	Antibody 2D03 Light Chain translated sequence		
<400>	4		
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln	1	5	10
Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Thr Asn Ile Gly Lys Asn	20	25	30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu	35	40	45

